How Healthy is European Biotech? - Comparative study on biotech in Europe

13.04.2005

Critical I

In a political Europe, biotechnology has tended to become synonymous with genetically modified plants, the foods and feeds derived from them, and the environments into which they are released. This preoccupation with “GMOs” is not only scientifically unwarranted, it is also economically inappropriate. Plant biotechnology, although an important part, represents just a fraction of the biotechnology landscape both in Europe and in the United States. Agricultural biotechnology companies – including those covering both plant and animal applications – account for just 5% of US companies in the field. In Europe, the figure is slightly higher at 7%, but this is matched by the 7% of European companies that use biotechnologies such as biosensing, bioscrubbing, bioremediation, and water treatment to benefit the environment directly.

  • Biotechnology in Europe - presentation by John Hodgson at BioVision (Lyon, 2005)

  • European biotech myths - presentation by Keith Binding, at EuropaBio Open Session - Biotechnology – a real opportunity to create growth and jobs (June 2005)